Glipizide — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Type 2 Diabetes Mellitus

• Canagliflozin
• Dapagliflozin
• Dulaglutide
• Empagliflozin
• Glimepiride
• Insulin Glargine
• Metformin
• Pioglitazone

Other medications in Diabetes & Metabolism

• Glyburide
• Insulin Aspart
• Insulin Degludec
• Insulin Detemir
• Insulin Lispro
• Linagliptin
• Liraglutide
• Liraglutide (Obesity)

What Glipizide is approved for (FDA label)

Glipizide Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Glipizide (FDA label)

In U.S. and foreign controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was glipizide discontinued. Hypoglycemia See PRECAUTIONS and OVERDOSAGE sections. Gastrointestinal Gastrointestinal disturbances are the most common reactions. Gastrointestinal complaints were reported with the following approximate incidence: nausea and diarrhea, one in seventy; constipation and gastralgia, one in one hundred. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas: glipizide should be discontinued if this occurs. Dermatologic Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in seventy patients.

Source: FDA prescribing information (DailyMed). Set ID: 00729e82-150a-464a-abe7-a3319721fbdb. SPL document ID: b56e8971-79df-4b04-ac58-dd399d61a62f. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Glipizide (FDA label)

Glipizide is contraindicated in patients with: 1. Known hypersensitivity to the drug. 2. Type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.

Source: FDA prescribing information (DailyMed). Set ID: 00729e82-150a-464a-abe7-a3319721fbdb. SPL document ID: b56e8971-79df-4b04-ac58-dd399d61a62f. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Glipizide (FDA label)

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, quinolones and beta-adrenergic blocking agents. When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control. In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs. Certain drugs tend to produce hyperglycemia and may lead to loss of control.

Source: FDA prescribing information (DailyMed). Set ID: 00729e82-150a-464a-abe7-a3319721fbdb. SPL document ID: b56e8971-79df-4b04-ac58-dd399d61a62f. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.